NuCana PLC Accounts Payable Over Time
| NCNA Stock | USD 1.29 0.04 3.01% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out NuCana PLC Performance and NuCana PLC Correlation. NuCana |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NuCana PLC. If investors know NuCana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NuCana PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (14.77) | Return On Assets (0.68) | Return On Equity (1.81) |
The market value of NuCana PLC is measured differently than its book value, which is the value of NuCana that is recorded on the company's balance sheet. Investors also form their own opinion of NuCana PLC's value that differs from its market value or its book value, called intrinsic value, which is NuCana PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NuCana PLC's market value can be influenced by many factors that don't directly affect NuCana PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NuCana PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if NuCana PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NuCana PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Accounts Payable Analysis
Compare NuCana PLC and related stocks such as Effector Therapeutics, Virios Therapeutics Llc, and Zura Bio Limited Accounts Payable Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZURA | 7 K | 7 K | 7 K | 7 K | 7 K | 7 K | 7 K | 7 K | 7 K | 7 K | 7 K | 7 K | 2 M | 2.7 M | 1.7 M |
| ZVSA | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2 M | 6 M | 8.4 M | 5.2 M |
| CDTX | 32 K | 32 K | 32 K | 32 K | 1.2 M | 3.1 M | 2.9 M | 2.6 M | 2.8 M | 1.9 M | 4.6 M | 1.3 M | 1.4 M | 3.8 M | 2.6 M |
| SLN | 83 K | 1.3 M | 959 K | 1.7 M | 2 M | 1.1 M | 1.6 M | 2.7 M | 3.8 M | 6.9 M | 2.3 M | 4.1 M | 3.2 M | 2.6 M | 1.7 M |
| APLT | 713 K | 713 K | 713 K | 713 K | 713 K | 713 K | 713 K | 713 K | 3 M | 8.8 M | 640 K | 9.5 M | 4.5 M | 1.7 M | 1.7 M |
| CTMX | 930 K | 930 K | 930 K | 930 K | 1.9 M | 4.7 M | 6.6 M | 4.2 M | 5.1 M | 4.2 M | 3 M | 2.8 M | 2.8 M | 1.5 M | 2.7 M |
| RANI | 198 K | 198 K | 198 K | 198 K | 198 K | 198 K | 198 K | 198 K | 198 K | 198 K | 537 K | 1.1 M | 1.5 M | 648 K | 863.1 K |
| VINC | 35 K | 35 K | 35 K | 35 K | 35 K | 35 K | 35 K | 35 K | 35 K | 35 K | 491 K | 2 M | 4.1 M | 2.5 M | 2 M |
| TNYA | 600 K | 600 K | 600 K | 600 K | 600 K | 600 K | 600 K | 600 K | 600 K | 600 K | 1 M | 10.7 M | 9.6 M | 5.6 M | 6.1 M |
| CRVS | 57 K | 57 K | 57 K | 57 K | 57 K | 1.6 M | 1.9 M | 3.5 M | 2 M | 2.4 M | 3.5 M | 1.6 M | 2 M | 1.5 M | 2.2 M |
| ALXO | 697 K | 697 K | 697 K | 697 K | 697 K | 697 K | 697 K | 697 K | 697 K | 3.7 M | 4 K | 3.8 M | 8.1 M | 8.6 M | 4.6 M |
| MREO | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 3.2 M | 3 M | 4.6 M | 6.4 M | 2.9 M | 2.3 M | 3.5 M | 2.3 M | 2.8 M |
| ABOS | 223 K | 223 K | 223 K | 223 K | 223 K | 223 K | 223 K | 223 K | 223 K | 223 K | 531 K | 1.1 M | 1.6 M | 1.4 M | 1.1 M |
| DAWN | 69 K | 69 K | 69 K | 69 K | 69 K | 69 K | 69 K | 69 K | 69 K | 69 K | 202 K | 1.7 M | 260 K | 2.6 M | 2.7 M |
| INZY | 984 K | 984 K | 984 K | 984 K | 984 K | 984 K | 984 K | 984 K | 984 K | 901 K | 3.1 M | 2.4 M | 2.5 M | 1.2 M | 2 M |
NuCana PLC and related stocks such as Effector Therapeutics, Virios Therapeutics Llc, and Zura Bio Limited Accounts Payable description
An accounting item on the balance sheet that represents NuCana PLC obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of NuCana PLC are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.My Equities
My Current Equities and Potential Positions
Check out NuCana PLC Performance and NuCana PLC Correlation. For information on how to trade NuCana Stock refer to our How to Trade NuCana Stock guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
NuCana PLC technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.